TNFSF10 and prostate cancer: For example, tunicamycin treatment enhanced the susceptibility of human non-small cell lung cancer cells to EGFR tyrosine kinase inhibitor erlotinib [25], and also stimulated TRAIL–induced apoptosis in human prostate cancer PC-3 cells [26].